Cypress Asset Management Inc. TX reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,577 shares of the biopharmaceutical company’s stock after selling 1,343 shares during the period. Cypress Asset Management Inc. TX’s holdings in Regeneron Pharmaceuticals were worth $3,835,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the company. FMR LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after acquiring an additional 416,192 shares during the period. BlackRock Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after acquiring an additional 41,406 shares during the period. Vanguard Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 2.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after acquiring an additional 148,962 shares during the period. Artisan Partners Limited Partnership lifted its stake in shares of Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after acquiring an additional 29,252 shares during the period. Finally, Polen Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 2nd quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock worth $779,105,000 after purchasing an additional 108,413 shares in the last quarter. 66.51% of the stock is owned by institutional investors.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at $4,950,000. The disclosure for this sale can be found here. Insiders sold 61,460 shares of company stock valued at $29,143,390 over the last three months. Insiders own 10.80% of the company’s stock.

Regeneron Pharmaceuticals, Inc. (REGN) traded down $2.88 during mid-day trading on Monday, reaching $388.71. 241,521 shares of the company’s stock traded hands, compared to its average volume of 900,908. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The company has a market capitalization of $42,072.04, a P/E ratio of 33.90, a price-to-earnings-growth ratio of 1.54 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 12 month low of $340.09 and a 12 month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.13 earnings per share. sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Cypress Asset Management Inc. TX” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-shares-sold-by-cypress-asset-management-inc-tx/1716076.html.

REGN has been the topic of a number of research reports. Canaccord Genuity set a $522.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 28th. UBS AG reiterated a “buy” rating and issued a $535.00 target price (up from $489.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 4th. Citigroup Inc. boosted their target price on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the stock a “buy” rating in a report on Friday, August 4th. Credit Suisse Group reiterated a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 11th. Finally, Guggenheim reiterated a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $475.34.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.